intestinal diseases; medullary carcinoma; a family history of medullary carcinoma or multiple endocrine neoplasm type-2 syndrome; liver or renal disease; creatinine clearance less than 60 mL/min; active or untreated malignancy; acute or chronic pancreatitis; haemoglobin-opathy; haemolytic or chronic anaemia; two or more episodes of major hypoglycaemia within 6 months; and use of excluded drugs (insulin, Î±-gluco sidase inhibitors, meglitinides, DPP-4 inhibitors, GLP-1 receptor agonists, or rosiglitazone). The study was approved at each site by an institutional review board in accordance with the Declaration of Helsinki. 20 All patients gave written  informed consent before participating. Randomisation and masking